1322.9
-46.80 (-3.42%)
EMCURE • 12 Nov, 2025 | 12:59 PM
Emcure Pharmaceuticals Stock Performance
|
|
|
Emcure Pharmaceuticals Company background
Founded in: 1981
Managing director: SATISH RAMANLAL MEHTA
Emcure Pharmaceuticals Limited was originally incorporated as Emcure Pharmaceuticals Private Limited, as a Private Company, pursuant to a Certificate of Incorporation dated April 16, 1981 issued by Registrar of Companies, Maharashtra at Bombay. Subsequently, Company was converted into a Public Company and the name of Company was changed to Emcure Pharmaceuticals Limited, through a fresh Certificate of Incorporation issued by the RoC, Maharashtra in Pune on September 18, 2001.Emcure Pharmaceuticals an Indian pharmaceutical company engaged in developing, manufacturing and globally marketing a broadrange of pharmaceutical products across several major therapeutic areas. In India, they are present across acute and chronic therapeutic areas, and their key therapeutic areas include gynecology, cardiovascular, vitamins, minerals and nutrients, human immunodeficiency virus antivirals, bloodrelated and oncology/antineoplastics. The Company has 13 manufacturing facilities across India. It keeps a strong track record in developing portfolios of differentiated products, including chiral molecules, complex APIs, biologics and novel drug delivery systems. It has a portfolio of 11 chiral molecules, of which 6 have been launched so far.In year 1999, Lasor Drugs Limited was amalgamated with the Company. Thereafter, Emcure Laboratories Private Limited., Lasor Laboratories Limited, Lasor Remedies Limited, Nucron Pharmaceuticals Limited and Hiraral Mehta Sales Private Limited were amalgamated with Company during the period 2001. The Company established facility in Kurkumbh in 2006 and then started operations of injectables facility in Hinjawadi. The facility established by Companys Subsidiary, Gennova Biopharmaceuticals Limited at Hinjawadi became operational.The Company started operations in solid orals at facility in Jammu in 2009. During 2012, it acquired rights of BiCNUr, a branded oncology product prescribed for treatment of brain tumors, multiple myeloma, Hodgkins disease and nonHodgkins lymphoma. Through Subsidiary, Zuventus Healthcare Limited, a manufacturing facility was established in Bengaluru in year 2017 and finally, the Company received licence to work a factory at Sanand, Gujarat in 2018. The subsidiary, Tillomed France S.A.S., was incorporated in France in 2018. The Subsidiary, Emcure Pharma Chile SpA, was incorporated in Chile in 2020. The Company has a portfolio of six commercialized and inhouse manufactured biologics and biologics brands, Elaxim, Tenectase and Hamsyl, each launched into domestic market for the Financial Year 2021. The Company launched biosimilar for Tenecteplase,commonly used for acute myocardial infraction, and the biosimilar for Pegylatedasparaginase, commonly used for treating patients with leukemia. It hold the global patent for use of Tenectaplase to treat Acute Ischemic Stroke as a second indication in 2021 and Emcure Pharma Philippines Inc., incorporated in Philippines in 202122. Tillomed Malta Ltd, was incorporated in Malta in 202223. In July 2024, the Company came up with an Initial Public Offer of issuing 19,375,070 Equity Shares aggregating to Rs 1952.02 Crore comprising a Fresh Issue of 7,946,231 Equity Shares aggregating to Rs 800 Crore and an Offer for Sale of 11,428,839 Equity Shares aggregating to Rs 1152.02 Crore.In FY2025, Emcure entered this highgrowth sector with the launch of Emcutix Biopharmaceuticals, a wholly owned subsidiary that consolidates its dermatology operations. The Company entered the fastgrowing consumer health segment under the Arth brand, targeting lifestyle and wellness categories with sciencebacked formulations.
Emcure Pharmaceuticals Financial Highlights
Emcure Pharmaceuticals reported a Q2 FY 2025-26
revenue of ₹2269.82 crore,
up 18.6% YoY,
with net profit increased
34.1% to ₹251.37 crore. For the full year FY2025–2026, revenue
reached ₹7963.26 crore and profit touched at
₹707.47 crore. As of Sep '25, Emcure Pharmaceuticals’s market capitalisation stood at ₹25,964.70 crores.
Shareholding as of Sep '25 shows promoters holding 77.9%, with FIIs at
3.3%, DIIs at 4.3%, and public at 14.5%.
Emcure Pharmaceuticals Share Price Today
As of 12 Nov 2025, Emcure Pharmaceuticals share price is ₹1325.9. The stock opened at ₹1372.8 and had closed at ₹1369.7 the previous day. During today’s trading session, Emcure Pharmaceuticals share price moved between ₹1,322.20 and ₹1,408.00, with an average price for the day of ₹1365.10. Over the last 52 weeks, the stock has recorded a low of ₹889.00 and a high of ₹1,519.90. In terms of performance, Emcure Pharmaceuticals share price has increased by 31.6% over the past six months and has increased by 6.18% over the last year.
Emcure Pharmaceuticals Fundamental
Market Cap (in crs)
25,964.70
Face Value
10
Turnover (in lacs)
1,679.51
Key Metrics
Qtr Change %
49.15% Gain from 52W Low
-4.6
Dividend yield 1yr %
Below industry Median
0.2
Emcure Pharmaceuticals Key Financials
Loading chart...
Loading chart...
Loading chart...
Loading chart...
Emcure Pharmaceuticals Quarterly Revenue
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
2269.82 Cr | 2100.54 Cr | 2116.24 Cr | 1962.63 Cr | 2001.98 Cr |
Emcure Pharmaceuticals Yearly Revenue
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
7963.26 Cr | 6715.24 Cr | 6031.72 Cr | 5918.86 Cr |
Emcure Pharmaceuticals Quarterly Net Profit/Loss
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|
251.37 Cr | 214.79 Cr | 197.24 Cr | 156.09 Cr | 201.55 Cr |
Emcure Pharmaceuticals Yearly Net Profit/Loss
| Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|
707.47 Cr | 527.58 Cr | 561.84 Cr | 702.56 Cr |
Emcure Pharmaceuticals Result Highlights
Result Summary
-
Emcure Pharmaceuticals Ltd reported a 8.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 11.5%.
-
Its expenses for the quarter were up by 6.7% QoQ and 9.5% YoY.
-
The net profit increased 17.0% QoQ and increased 24.7% YoY.
-
The earnings per share (EPS) of Emcure Pharmaceuticals Ltd stood at 12.85 during Q2 FY 2025-26.
Data Source: BSE, Company announcements
The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results.
Emcure Pharmaceuticals Technical Analysis
Moving Averages Analysis
Moving Averages Analysis
1322.9
Current Price
Day EMA5
1,372.30
Day EMA10
1,362.50
Day EMA12
1,360.90
Day EMA20
1,358.70
Day EMA26
1,358.80
Day EMA50
1,359.30
Day EMA100
1,340.40
Day EMA200
1,328.10
Day SMA5
1,368.50
Day SMA10
1,349.10
Day SMA20
1,356.20
Day SMA30
1,355.10
Day SMA50
1,355.70
Day SMA100
1,365.30
Day SMA150
1,291.10
Day SMA200
1,237.80
Delivery & Volume
| Period | Combined Delivery Volume | NSE+BSE Traded Volume |
|---|---|---|
Day Rs | 185990 Rs | 458582 Rs |
Week Rs | 283694 Rs | 512214 Rs |
Month Rs | 116947 Rs | 188533 Rs |
Resistance & Support
1,395.30
Pivot
Resistance
First Resistance
1,428.20
Second Resistance
1,486.70
Third Resistance
1,519.60
Support
First Support
1,336.80
Second support
1,303.90
Third Support
1,245.40
Relative Strength Index
51.78
Money Flow Index
50.52
MACD
2.12
MACD Signal
-2.78
Average True Range
47.89
Average Directional Index
18.12
Rate of Change (21)
-1.87
Rate of Change (125)
32.33
Emcure Pharmaceuticals Peer comparison
Compare
| Index Name | Market Price | Market Cap | 52W Low | 52W High | Prev. Close | 1W Return | 1M Return | 6M Return | 1Y Return | 3Y Return | Dividend Yield | PE Ratio | Industry PE | PB Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1,829.50 | 28,632.06 | 1385.75 | 1952 | 1,828.40 | 7.72% | 9.33% | 17.49% | 2.81% | 83.85% | 0.84% | 42.24 | 40.20 | 8.47 | |
4,996.00 | 22,860.14 | 3701 | 5993 | 4,997.00 | -2.33% | -6.32% | 17.57% | -5.47% | 15.87% | 3.30% | 33.81 | 40.20 | 5.42 | |
645.75 | 25,985.56 | 599.55 | 960.6 | 644.90 | -0.12% | -0.85% | 3.22% | -27.39% | 4.73% | 0.19% | 59.43 | 86.60 | 5.63 | |
690.30 | 26,437.30 | 687.05 | 1360 | 691.05 | -7.06% | -23.70% | -35.08% | -42.69% | 55.53% | 0.00% | 74.90 | 40.20 | 11.36 | |
1,848.50 | 30,499.71 | 1277.8 | 2131 | 1,851.20 | -3.31% | -3.89% | 29.26% | 4.76% | 6.81% | 0.97% | 26.35 | 40.20 | 3.03 | |
194.26 | 25,816.66 | 181.73 | 283.9 | 194.22 | -3.07% | -3.68% | -8.37% | -22.48% | 41.38% | 0.07% | 36.58 | 40.20 | 3.33 |
Emcure Pharmaceuticals Share Price FAQs
What is Share Price of Emcure Pharmaceuticals ?
Emcure Pharmaceuticals share price is ₹1322.9 in NSE and ₹1322.8 in BSE as on 12/11/2025.
How has Emcure Pharmaceuticals shares performed in the past ?
Emcure Pharmaceuticals share price in the past 1-year return was -5.9. The Emcure Pharmaceuticals share hit a 1-year low of Rs. 889 and a 1-year high of Rs. 1519.9.
What is the market cap of Emcure Pharmaceuticals ?
The market cap of Emcure Pharmaceuticals is Rs. 25964.7 Cr. as of 12/11/2025.
What is the current P/E ratio of Emcure Pharmaceuticals ?
The PE ratios of Emcure Pharmaceuticals is 64.47 as of 12/11/2025.
What is the current PB ratio of Emcure Pharmaceuticals ?
The PB ratios of Emcure Pharmaceuticals is 8.57 as of 12/11/2025
What is the Mutual Fund shareholding in Emcure Pharmaceuticals ?
The Mutual Fund Shareholding in Emcure Pharmaceuticals was 3.58% at the end of 12/11/2025.
How to buy Emcure Pharmaceuticals shares?
You can easily buy Emcure Pharmaceuticals shares in Kotak Securities by opening a demat account and getting the KYC documents verified online.
What is the 52-week high and low of Emcure Pharmaceuticals ?
The 52-week high and low of Emcure Pharmaceuticals share price is ₹1519.9 and ₹889 as of 12/11/2025.
What is the EPS of Emcure Pharmaceuticals ?
The earnings per share (EPS) of Emcure Pharmaceuticals stood at 12.85 during Q2 FY 2025-26.
Please be aware that Emcure Pharmaceuticals stock prices are subject to continuous fluctuations due to various factors.
Invest in Emcure Pharmaceuticals